Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02127970 · ClinicalTrials.gov registry record · Phase 3
Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3 study, sponsored by Durata Therapeutics Inc., an affiliate of Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 698
- Enrollment target
NCT02127970 is a Phase 3 study that has completed, run by Durata Therapeutics Inc., an affiliate of Allergan. The registered enrollment target is 698 participants.
The verdict
NCT02127970, a Phase 3 study, has completed, sponsored by Durata Therapeutics Inc., an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 698 participants
- Enrollment target
Study Summary
To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected Gram-positive acute bacterial skin and skin structure infections (ABSSSI) at 48 -72 hours after initiation of treatment.
Interventions
- DRUG Dalbavancin
- DRUG Dalbavancin-matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 698 participants |
| Start Date | 2014-04-18 |
| Est. Completion | 2015-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02127970
The ClinicalTrials.gov registry entry for NCT02127970 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 698 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durata Therapeutics Inc., an affiliate of Allergan, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dalbavancin is the first listed.
NCT02127970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02127970 about?
NCT02127970 is a clinical study titled "Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections". To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected Gram-positive acute bacterial skin and skin structure infections (ABSSSI) at 48 -7...
What is the current status of trial NCT02127970?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 698 participants. The study started on 2014-04-18. Estimated completion is 2015-03-11.
What interventions are being tested in trial NCT02127970?
The interventions under investigation include: Dalbavancin (DRUG), Dalbavancin-matching Placebo (DRUG).
Who is sponsoring clinical trial NCT02127970?
This trial is sponsored by Durata Therapeutics Inc., an affiliate of Allergan, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.